Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis

Published:2022-09-25 Issue:3 Volume:55 Page:641-651
ISSN:1573-2584
Container-title:International Urology and Nephrology
language:en
Short-container-title:Int Urol Nephrol

Author:

Chen Miaomiao,Zhang Xuehan,Xiong Yi,Xu Gaosi^ORCID

Funder

National Natural Science Foundation of China

Nature Science Foundation of Jiangxi Province

Projects in the Second Affiliated Hospital of Nanchang University

Publisher

Springer Science and Business Media LLC

Subject

Urology,Nephrology

Link

https://link.springer.com/content/pdf/10.1007/s11255-022-03372-5.pdf

Reference49 articles.

1. Glassock RJ (2010) The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis 56(1):157–167. https://doi.org/10.1053/j.ajkd.2010.01.008

2. Couser WG (2017) Primary Membranous Nephropathy. Clin J Am Soc Nephrol 12(6):983–997. https://doi.org/10.2215/cjn.11761116

3. Medrano AS et al (2015) Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens. Biomarkers 20(1):77–83. https://doi.org/10.3109/1354750x.2014.993708

4. Tomas NM et al (2014) Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 371(24):2277–2287. https://doi.org/10.1056/NEJMoa1409354

5. Keri KC et al (2019) Primary membranous nephropathy: comprehensive review and historical perspective. Postgrad Med J 95(1119):23–31. https://doi.org/10.1136/postgradmedj-2018-135729

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels;BMC Nephrology;2023-09-22

2. Research Progress of Rituximab in the Treatment of Idiopathic Membranous Nephropathy;Advances in Clinical Medicine;2023